SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-371540"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-371540" > Myeloablative vs re...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008184naa a2200805 4500
001oai:DiVA.org:uu-371540
003SwePub
008190107s2018 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:142588656
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3715402 URI
0247 a https://doi.org/10.1182/bloodadvances.20180248442 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1425886562 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Chhabra, Saurabhu Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA4 aut
2451 0a Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
264 c 2018-11-05
264 1b American Society of Hematology,c 2018
338 a print2 rdacarrier
520 a Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for International Blood and Marrow Transplant Research database, we sought to determine whether reduced-intensity/nonmyeloablative conditioning (RIC) allo-HCT and myeloablative conditioning (MAC) result in similar outcomes in CML patients. We evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years. The disease status at transplant was divided into the following categories: chronic phase 1, chronic phase 2 or greater, and accelerated phase. Patients in blast phase at transplant and alternative donor transplants were excluded. The primary outcome was overall survival (OS) after allo-HCT. MAC (n = 1204) and RIC allo-HCT recipients (n = 191) from 2007 to 2014 were included. Patient, disease, and transplantation characteristics were similar, with a few exceptions. Multivariable analysis showed no significant difference in OS between MAC and RIC groups. In addition, leukemia-free survival and nonrelapse mortality did not differ significantly between the 2 groups. Compared with MAC, the RIC group had a higher risk of early relapse after allo-HCT (hazard ratio [HR], 1.85; P = .001). The cumulative incidence of chronic graft-versus-host disease (cGVHD) was lower with RIC than with MAC (HR, 0.77; P = .02). RIC provides similar survival and lower cGVHD compared with MAC and therefore may be a reasonable alternative to MAC for CML patients in the TKI era.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
7001 a Ahn, Kwang Woou Med Coll Wisconsin, Inst Hlth & Soc, Dept Biostat, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut
7001 a Hu, Zhen-Huanu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut
7001 a Jain, Sandeepu Med Univ South Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA4 aut
7001 a Assal, Ameru Columbia Univ, Med Ctr, New York, NY USA4 aut
7001 a Cerny, Janu UMass Mem Med Ctr, Worcester, MA USA4 aut
7001 a Copelan, Edward A.u Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA4 aut
7001 a Daly, Andrewu Tom Baker Canc Clin, Calgary, AB, Canada4 aut
7001 a DeFilipp, Zachariahu Massachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA 02114 USA4 aut
7001 a Gadalla, Shahinaz M.u NCI, Div Canc Epidemiol & Genet, Clin Genet Branch, NIH, Rockville, MD USA4 aut
7001 a Gale, Robert Peteru Imperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England4 aut
7001 a Ganguly, Siddharthau Univ Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA4 aut
7001 a Hamilton, Betty K.u Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA4 aut
7001 a Hildebrandt, Gerhard Carlu Univ Kentucky, Markey Canc Ctr, Lexington, KY USA4 aut
7001 a Hsu, Jack W.u Shands HealthCare, Dept Med, Div Hematol & Oncol, Gainesville, FL USA;Univ Florida, Gainesville, FL USA4 aut
7001 a Inamoto, Yoshihirou Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan4 aut
7001 a Kanate, Abraham S.u West Virginia Univ, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506 USA4 aut
7001 a Khoury, H. Jeanu Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA4 aut
7001 a Lazarus, Hillard M.u Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Seidman Canc Ctr, Cleveland, OH 44106 USA4 aut
7001 a Litzow, Mark R.u Mayo Clin Rochester, Div Hematol & Transplant Ctr, Rochester, MN USA4 aut
7001 a Nathan, Sunitau Rush Univ, Med Ctr, Chicago, IL 60612 USA4 aut
7001 a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden4 aut0 (Swepub:uu)riols677
7001 a Pawarode, Attapholu Univ Michigan, Dept Internal Med, Div Hematol Oncol, Med Sch,Blood & Marrow Transplantat Program, Ann Arbor, MI 48109 USA4 aut
7001 a Ringden, Olleu Karolinska Institutet4 aut
7001 a Rowe, Jacob M.u Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel4 aut
7001 a Saad, Aymanu Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA4 aut
7001 a Savani, Bipin N.u Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA4 aut
7001 a Schouten, Harry C.u Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands4 aut
7001 a Seo, Sachikou Natl Canc Res Ctr East, Dept Hematol & Oncol, Chiba, Japan4 aut
7001 a Shah, Nirav N.u Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA4 aut
7001 a Solh, Melhemu Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA4 aut
7001 a Stuart, Robert K.u Med Univ South Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA4 aut
7001 a Ustun, Celalettinu Univ Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA4 aut
7001 a Woolfrey, Ann E.u Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA4 aut
7001 a Yared, Jean A.u Univ Maryland, Greenebaum Canc Ctr, Div Hematol Oncol, Blood & Marrow Transplantat Program,Dept Med, Baltimore, MD 21201 USA4 aut
7001 a Alyea, Edwin P.u Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA4 aut
7001 a Kalaycio, Matt E.u Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA4 aut
7001 a Popat, Udayu Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA4 aut
7001 a Sobecks, Ronald M.u Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA4 aut
7001 a Saber, Waelu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut
7102 a Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USAb Med Coll Wisconsin, Inst Hlth & Soc, Dept Biostat, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 org
7730 t Blood Advancesd : American Society of Hematologyg 2:21, s. 2922-2936q 2:21<2922-2936x 2473-9529x 2473-9537
8564 u https://europepmc.org/articles/pmc6234373?pdf=render
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-371540
8564 8u https://doi.org/10.1182/bloodadvances.2018024844
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:142588656

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy